 The initial procedure will be repeated after one to two weeks unless clinical circumstances dictate otherwise that is, the patient declined a second injection because of increase in pain or satisfaction with pain relief. The rationale for the repeat procedure is to allow possible benefit from a cumulative effect of the procedures andor the injectates. Between the first injection and first follow-up visit, no patient will be allowed any additional therapeutic interventions. Nerves to be targeted by the injection will be decided by the treating physician based on area of the foot and ankle that displays features of neuropathic pain. Each injection of study medications will be preceded by subcutaneous injections of 1 mLs of LA 2 lidocaine at each of the injection sites. This will reduce discomfort of the study participants from the injections. The subcutaneous LA will also cause numbness of the skin and this will ensure blinding of participants to their group allocation. Two ultrasound-guided procedures will be performed at weekly intervals over two weeks. The US-guided technique for performing these procedures has been described in previous studies from our center.22 Conservative measures oral analgesics, physiotherapy will continue during the study. Fasting blood glucose will be measured at baseline and at one month following the interventions. Systolic and diastolic blood pressure with participant sitting for at least 5 minutes prior to the measurement values will be recoded as a mean of three consecutive readings at baseline and at one month following the interventions. Cross-sectional area CSA of tibial nerve at 3 cm proximal to cephalad edge of medial malleolus will also be measured prior to the first procedure and prior to the second procedure in participants with pain in distribution of the tibial nerve. Change in CSA if any will be correlated with analgesic response to perineural injections because decrease in CSA may indicate reduction in edema of the nerve. 